Industry Satellite Symposia

The American Society for Radiation Oncology (ASTRO) has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposium. The symposia constitute the content and views of the provider and are not part of the official ASTRO Annual Meeting program.

Saturday, September 28, 2024

6:15 p.m. - 6:45 p.m.: Registration and Dinner
6:45 p.m. - 8:45 p.m.: Symposium (will be livestreamed)

The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal is Cure

For more information or to register, please visit gotoper.com/radonc.

Location: Marriott Marquis Washington, DC
Liberty Ballroom, Salons M/N/O/P
901 Massachusetts Avenue NW
Washington, DC

CME Credits: Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This educational activity is directed toward radiation oncologists and other oncology health care professionals interested in SCLC. PER will launch a digital marketing campaign to recruit audience.

Learning Objectives:

• Explain the underlying principles of immunotherapy in treating early-stage and locally advanced non-small cell lung cancer (NSCLC) and the importance of collaboration among thoracic surgeons, medical oncologists, radiologists, and radiation oncologists in optimizing patient care.
• Analyze the most recent clinical trial findings and evolving patterns in the use of immune checkpoint inhibitors for treating early-stage NSCLC.
• Formulate individualized treatment plans by combining the most up-to-date safety and efficacy data with innovative immunotherapy-based strategies for treating patients with early to locally advanced stage I-III NSCLC.
• Design optimal care plans for the treatment of early to locally advanced NSCLC that incorporates multidisciplinary approaches to effectively detect, monitor, and address immune-related adverse events (irAEs).

Topics: This activity will cover integrating immunotherapy in the context of multidisciplinary care in Stage I-III NSCLC, coordination of the lung cancer care team to integrate immunotherapy in resectable NSCLC, building on current immunotherapeutic standards for combined modality therapy in unresectable stage III NSCLC, and the multidisciplinary approach to managing immune-related adverse events in NSCLC.

Faculty: 

1. Percy Lee, MD, FASTRO (Chair)
2. Julia Rotow, MD
3. David H. Harpole Jr, MD

This activity is independently supported through an educational grant from Merck & Co, Inc.

Sunday, September 29, 2024

6:00 p.m. - 6:30 p.m.: Registration and Dinner
6:30 p.m. - 8:30 p.m.: Symposium (will be livestreamed)

New Frontiers in Immunotherapy for SCLC: Insights from the Latest Clinical Trials and Their Application in Real-World Treatment

For more information or to register, please visit gotoper.com/radonc.

Location: Marriott Marquis Washington, DC
Marquis Ballroom 3-4
901 Massachusetts Avenue NW
Washington, DC

CME Credits: Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This educational activity is directed toward radiation oncologists and other oncology health care professionals interested in SCLC. PER will launch a digital marketing campaign to recruit audience.

Learning Objectives:

• Analyze safety and efficacy data from clinical trials to optimize the efficacy and safety of SCLC treatment approaches in multiple lines of care and a variety of real-world case-based scenarios.
• Implement clinical strategies to mitigate and manage treatment-related adverse events in patients with SCLC.
• Evaluate the rationale for augmenting standard regimens used in the management of SCLC.
• Recognize emerging strategies for the treatment of limited- and extensive-stage SCLC in the context of highly anticipated ongoing trial data.

Topics: This activity will cover integrating multiple therapeutic modalities in curative settings for limited-stage small cell lung cancer, case discussion around the utilization of immunotherapy for LS-SCLC, followed by extensive stage SCLC first-line and subsequent therapies with best practices and updates on novel strategies, and case studies in ES-SCLC and the use of immunotherapy for treatment.

Faculty: 

1. Megan E. Daly, MD (Chair)
2. Chul Kim, MD
3. Nagla Abdel Karim, MD

This activity is independently supported through an educational grant from AstraZeneca, Inc.